Scientific communications company Envision Pharma has bought Two Labs, a firm specialising in commercial solutions for the pharma and biotech sector, for an undisclosed sum.
The combined company will bring together complementary clients, services, and technologies, extending Envision’s scientific footprint to new clients in the “product pre-launch setting” – while opening up new business avenues and geographies for Two Lab’s launch planning services.
Excellere Partners, a US-based private equity firm focused on partnering with entrepreneurs and management teams in emerging growth companies, will exit its investment in Two Labs following a four-year partnership.
Two Labs, founded in 2003 and headquartered in Powell, Ohio, has offices and operations across the US and UK, and is an established strategic consulting and marketing provider to the biopharma industry.
Two Labs helps pharmaceutical companies develop and execute customised launch strategies for products.
Envision’s acquisition of Two Labs follows the recent announcement of GHO Capital’s increased investment in the company and the backing of management for its continued global expansion.
Since being founded in 2001, Envision has delivered strong year-on-year organic growth and established leadership in medical affairs strategy, medical communications, and enterprise-wide Envision technology.
The acquisition followed an investment in Envision by specialist European fund Global Healthcare Opportunities (GHO) earlier this month.
The transaction sees GHO lead a consortium of its investors headed by Mubadala Investment Company, and including HarbourVest Partners and Northwestern Mutual to drive a new phase of growth, while Ardian exits its investment following a four-year partnership with Envision and GHO.
The post Envision acquires commercial solutions firm Two Labs appeared first on .